[테크월드뉴스=조명의 기자]
The three ministries of the Ministry of Health and Welfare (hereinafter the Ministry of Welfare), the Ministry of Science and Technology Information and Communication (hereinafter the Ministry of Science and Technology) and the Ministry of Trade, Industry and Energy (hereinafter the Ministry of Industry) officially established the former head of the New Drug Development Project by Mok Hyeon-sang as the first head of the national drug development project on March 4. Appointed.
The three ministries started public offering in December 2020, and finally selected the first head of the National New Drug Development Project through the verification of application qualifications, the first (written), and the second (announcement) evaluation, and the deliberation and resolution of the Board of Directors of the National New Drug Development Foundation. Revealed.
The national new drug development project is a project that supports the entire cycle of new drug development, from effective and lead substances to candidate substance discovery, non-clinical, clinical phases 1 and 2, and commercialization, for a total of 2,175.8 billion won for 10 years from July 2021 to 2030. It is a super-large cross-ministerial new drug research and development project with KRW 1,4747 billion in government expenditure and 71.1 billion KRW in private sector.
This project aims to create global new drugs with annual sales of more than KRW 1 trillion and to develop new drugs made in Korea.It is a project to mobilize R&D capabilities of relevant ministries, and is a core project of the government that will determine the direction of the Korean pharmaceutical and bio industry over the next 10 years can do.
The head of the project manager will approve new drugs by global regulatory agencies such as the Ministry of Food and Drug Safety, the US FDA, and the European EMA.
With the aim of technology transfer at home and abroad, it will be in charge of discovering candidates, planning, evaluating, and managing clinical research projects, operating the project group, and supporting external cooperation such as cooperation with global pharmaceutical companies, and commercialization support.
New Director Mook is an expert with rich experience and knowledge in the development and commercialization of new drugs, such as successful technology transfer with global pharmaceutical companies in 2010, when he served as the CEO of Medifront DV.
In December 2016, the new head of the new head of the new drug development project was inaugurated as the 3rd head of the new drug development project (welfare, science, and industry), the predecessor of the national new drug development project. It has contributed to the achievements of two product approvals (one each approved by the Ministry of Food and Drug Safety) and 57 cases of technology transfer (15 trillion won in fixed-rate technology fees).
The official term of office of the project manager is three years, until March 3, 2024, and can be served for two years after evaluation.
New business manager Mook Hyun-sang expressed his ambition, “Based on the experience and know-how accumulated while operating the preceding business group, we will do our best to launch the global market for domestic new drugs, while making active investments in discovering materials in the early stages.”